To include your compound in the COVID-19 Resource Center, submit it here.
Amgen granted Daiichi exclusive rights to commercialize nine biosimilars in Japan. Amgen will be responsible for development
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury